Uso de factor VII en el control de sangrados perioperatorios: evidencias actuales / Recombinant activated factor VII for perioperative bleeding
Rev. méd. Chile
;
137(6): 837-843, jun. 2009. ilus, tab
Artigo
em Espanhol
| LILACS
| ID: lil-524966
ABSTRACT
Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Hemostáticos
/
Fator VIIa
/
Hemorragia Pós-Operatória
Limite:
Humanos
Idioma:
Espanhol
Revista:
Rev. méd. Chile
Assunto da revista:
Medicina
Ano de publicação:
2009
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Hospital Clínico Pontificia Universidad Católica de Chile/CL
Similares
MEDLINE
...
LILACS
LIS